Clinical Outcomes With Notch Inhibitors in Notch‐Activated Recurrent/Metastatic Adenoid Cystic Carcinoma
NOTCH inhibitors demonstrate activity in NOTCH-activated ACC, surpassing the efficacy of observation or prior systemic therapies. However, limited PFS and progression of nontarget lesions suggest the potential need for combination therapy to address ACC heterogeneity.
Authors
- Yoshitsugu Mitani (ORCID: https://orcid.org/0000-0002-8661-4702)
- Camilla O. Hoff (ORCID: https://orcid.org/0000-0002-4618-8438)
- Renata Ferrarotto (ORCID: https://orcid.org/0000-0002-3561-215X)
- Elena Lago
- Luana Guimarães de Sousa (ORCID: https://orcid.org/0000-0002-3516-7105)
- Adel K. El‐Naggar (ORCID: https://orcid.org/0000-0002-7175-9466)
- Flavia Bonini
- J.M. Siqueira (ORCID: https://orcid.org/0000-0002-3456-5371)
- Kaiwen Wang (ORCID: https://orcid.org/0000-0003-3857-4790)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Universidade de São Paulo (BR)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/cam4.70663
- Citations
- 6
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 12.04